Keros Therapeutics (KROS) Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KROS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Keros Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.80 |
| 52 Week High | US$22.55 |
| 52 Week Low | US$9.69 |
| Beta | 0.97 |
| 1 Month Change | 18.83% |
| 3 Month Change | 5.31% |
| 1 Year Change | -18.28% |
| 3 Year Change | -70.97% |
| 5 Year Change | -70.49% |
| Change since IPO | -41.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| KROS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.8% | 0.02% | 0.6% |
| 1Y | -18.3% | 36.1% | 19.5% |
Return vs Industry: KROS underperformed the US Biotechs industry which returned 36.1% over the past year.
Return vs Market: KROS underperformed the US Market which returned 19.5% over the past year.
Price Volatility
| KROS volatility | |
|---|---|
| KROS Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KROS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KROS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 87 | Jas Seehra | www.kerostx.com |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd.
Keros Therapeutics, Inc. Fundamentals Summary
| KROS fundamental statistics | |
|---|---|
| Market cap | US$238.10m |
| Earnings (TTM) | -US$85.14m |
| Revenue (TTM) | US$33.18m |
Is KROS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KROS income statement (TTM) | |
|---|---|
| Revenue | US$33.18m |
| Cost of Revenue | US$94.53m |
| Gross Profit | -US$61.35m |
| Other Expenses | US$23.80m |
| Earnings | -US$85.14m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.30 |
| Gross Margin | -184.89% |
| Net Profit Margin | -256.60% |
| Debt/Equity Ratio | 0% |
How did KROS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 23:58 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keros Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Corinne Johnson | Goldman Sachs |
| Andrew Fein | H.C. Wainwright & Co. |